Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

14/11/2018 06:30

Nov 14 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Sep 30, 2018        Sep 30, 2017     Dec 31, 2018 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              110 mln             409 mln                    
                   (-72.9 pct)        (+103.4 pct)                  
  Operating         loss 1.54         loss 424 mln                  
  Pretax            loss 1.55         loss 430 mln                  
  Net               loss 1.53         loss 411 mln                  
  EPS Basic      loss 17.16 yen       loss 5.11 yen                 
  EPS Diluted    loss 17.16 yen       loss 5.11 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div              NIL                 NIL                      
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T